HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 7,573-7,584 of 27,277
Drug study icon
CompletedNCT00035230

Topiramate for acute mania in bipolarity

About this title

A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder

Read the official source — NCT00035230
What is this study about?

This study evaluated the safety and effectiveness of Topiramate for people with bipolarity.

This study has finished and is no longer accepting participants.

Location not clearly listed
BipolarityMedication studyAges 16+
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT06982651

A Study on the Safety, Pharmacokinetics, and Food Effects of MI078 Capsules

Official study title

A Randomized, Double-Blind, Placebo-Parallel-Controlled Phase Ⅰ Clinical Trial of the Tolerability, Safety, Pharmacokinetics and Food Effects of MI078 Capsules in Single and Multiple Doses in Healthy Chinese Subjects

This study has finished and is no longer accepting participants.

In Changsha
DepressionMedication studyAges 18–45
Countries
China
Sponsor
Nanjing Minova Pharmaceutical Co., Ltd.
Behavioral study icon
CompletedACTRN12617000060347

A study that test the effects of a mobile phone application that delivers a psychological health intervention to reduce social anxiety symptoms.

Official study title

Randomised Controlled Trail testing the effectiveness of an Ecological Momentary Intervention (EMI) in adults with social anxiety symptoms

This study has finished and is no longer accepting participants.

In Australia
Anxiety, DepressionInterventional studyAges 18+
Countries
Australia
Sponsor
Australian National University
Other study type icon
CompletedNCT03666715

A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in adults with Schizophrenia in Portugal

Official study title

A Multicenter Retrospective Study to Analyse the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Patients With Schizophrenia in Portugal

This study has finished and is no longer accepting participants.

In Porto
SchizophreniaObservational studyAges 18–55
Countries
Portugal
Sponsor
Janssen-Cilag Farmaceutica Ltda.
Drug study icon
CompletedNCT04292197

18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers

Official study title

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single/Multiple Day Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of 18- Methoxycoronaridine (18-MC HCl) Administered Orally to Normal Healthy Volunteers

This study has finished and is no longer accepting participants.

In Perth
AddictionMedication studyAges 18–55
Countries
Australia
Sponsor
Definium Therapeutics US, Inc.
Drug study icon
CompletedNCT05145413

KarXT for schizophrenia

Official study title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Phoenix
SchizophreniaMedication studyAges 18–65
Countries
United States, United Kingdom, Bulgaria, + 5 others
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Drug study icon
CompletedNCT04659161

KarXT for schizophrenia

Official study title

A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Drug study icon
CompletedNCT04738123

KarXT for schizophrenia

Official study title

A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Bentonville
SchizophreniaMedication studyAges 18–65
Countries
United States, Ukraine
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Behavioral study icon
WithdrawnNCT05268497

Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy for treatment-resistant depression

Official study title

Assessment of Feasibility of Using Clinician-Directed Cognitive Behavior Therapy Supplemented by a Digital Application in Conjunction With Esketamine (SPRAVATO®) in Participants With Treatment-Resistant Depression

This study was withdrawn before enrollment.

Multiple locations, including New Haven
DepressionMedication studyAges 18–65
Countries
United States
Sponsor
Janssen Research & Development, LLC

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.